Recombinant Anti-CD3 x Anti-VEGFR2 Bispecific Antibody (scIgG) (SCIGG-109)

Recombinant Anti-CD3 x Anti-VEGFR2 Bispecific Antibody (scIgG) is designed to be expressed as two chains, each chain has the same units with their parental IgG antibodies, anti-CD3 and anti-VEGFR2 IgGs. The two chains form heterodimer via Fc KIH technology. This BsAb can retarget T cells to tumor cells. It is designed for the research of Colorectal cancer (CRC); Non-small cell lung cancer (NSCLC); Glioblastoma therapy.

Datasheet INQUIRY

Specifications

Targets

CD3 & VEGFR2

Type

Single chain IgGs

Species Reactivity

Human

Application

FuncS; Promising therapeutic agent

Related Disease

Colorectal cancer (CRC); Non-small cell lung cancer (NSCLC); Glioblastoma

Targets

Target 1

CD3

Gene ID

916

UniProt ID

P07766

Alternative Names

CD3; CD3E; CD3e molecule; Cluster of differentiation 3; CD3e molecule, epsilon (CD3-TCR complex); T3E; TCRE; IMD18; T-cell surface glycoprotein CD3 epsilon chain; CD3-epsilon; T-cell surface antigen T3/Leu-4 epsilon chain; CD3e antigen, epsilon polypeptide (TiT3 complex); T-cell antigen receptor complex, epsilon subunit of T3

Target 2

VEGFR2

Gene ID

3791

UniProt ID

A0A024RD88

Alternative Names

FLK1; CD309; VEGFR; VEGFR2; Vascular endothelial growth factor receptor 2; Kinase insert domain receptor; Fetal liver kinase 1; Kinase insert domain receptor, a type III receptor; KDR

Our products and services are for research use only, and not for use in diagnostic or therapeutic procedures.

Online Inquiry

Customer Reviews and Q&As

There are currently no customer reviews or questions for Recombinant Anti-CD3 x Anti-VEGFR2 Bispecific Antibody (scIgG) (SCIGG-109). Click the button below to contact us or submit your feedback about this product.

Recombinant Anti-CD3 x Anti-VEGFR2 Bispecific Antibody (scIgG) (CAT#: SCIGG-109)

Specifications

Targets

Customer Reviews and Q&As